Equities
Health CareMedical Equipment and Services
  • Price (EUR)4.13
  • Today's Change-0.025 / -0.60%
  • Shares traded66.74k
  • 1 Year change-9.63%
  • Beta0.5350
Data delayed at least 15 minutes, as of Feb 06 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

GVS SpA is an Italy-based manufacturer of filters and components for applications in the healthcare, life sciences, automotive, appliance, safety, commercial and industrial filtration. Its offering includes seven product lines: Healthcare, Laboratory, Mobility, Air Safety, Appliance, Personal Safety and Membranes. Each product line provides a suite of customizable solutions specifically related to each market. Additionally, the Company offers tailormade product and process development services, which cover all the project stages, including product and process design, validation, up to the mass production for large quantities. It is active globally.

  • Revenue in EUR (TTM)422.42m
  • Net income in EUR22.87m
  • Incorporated1992
  • Employees4.23k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ion Beam Applications SA596.63m17.00m475.43m2.10k27.653.8716.130.79690.56770.567720.174.060.97562.733.28281,693.602.781.5012.034.6431.2134.392.852.150.62097.410.363170.816.7512.01201.573.997.6925.86
Lumibird SA215.95m10.73m505.50m1.07k47.122.5316.612.340.47750.47759.618.900.50770.95934.42202,198.502.522.513.113.1763.8961.894.974.901.643.160.45830.001.7513.34-20.08-8.3815.27--
Revenio Group Oyj109.02m18.50m506.94m248.0027.414.6422.254.650.69310.69314.084.100.80872.916.94452,352.7013.6514.1115.7517.5371.8670.9616.8820.611.8010.720.103653.127.1915.91-3.2014.6422.935.92
medmix AG510.63m-6.33m528.44m2.67k--1.139.951.03-0.1696-0.169611.6010.390.47073.565.86174,403.90-0.49271.27-0.61991.5534.5235.24-1.052.651.101.870.4268140.79-0.55492.84-2,566.67--6.02--
RaySearch Laboratories AB (publ)121.13m20.55m532.65m450.0028.846.8811.734.406.396.3937.6926.820.65234.152.843,104,637.0011.072.9616.314.3792.9690.9316.975.801.55--0.30967.9016.629.96149.4932.190.5132--
Advanced Medical Solutions Group plc253.80m10.51m550.21m1.50k52.171.8615.712.170.04170.04171.011.170.57582.095.57137,690.002.385.092.635.5252.1955.064.1411.151.553.880.242833.4740.6611.64-55.35-17.818.3610.90
Synektik SA124.94m22.43m593.61m203.0026.4711.2423.494.7511.099.2061.8026.121.2211.183.60--21.9620.1136.1032.6734.9831.4017.9513.601.4142.090.153--9.1640.2951.5870.0228.82--
Arjo AB (publ)1.03bn31.32m619.73m6.94k21.200.94974.630.60071.231.2340.3927.380.7044.926.221,584,702.002.143.262.914.8042.5943.423.044.780.84944.190.417948.74-2.593.92-32.93-8.68--2.25
Xvivo Perfusion AB76.17m2.36m638.69m198.00271.353.2271.418.390.79680.796825.7667.100.340.89396.134,101,844.001.053.281.123.5273.8173.863.1010.873.681.830.05570.00-1.2535.19-85.39------
GVS SpA422.42m22.87m786.03m4.23k31.411.8211.551.860.13230.13232.352.280.4752.027.0199,768.772.576.013.338.5356.1157.985.4111.160.75672.400.4234--0.895913.51144.520.172923.38--
Paul Hartmann AG2.43bn81.51m800.22m10.09k9.760.67874.150.329822.9522.95682.93330.051.161.975.54240,745.704.124.215.455.7959.5657.303.563.351.1114.110.246537.952.321.95281.5813.2310.082.71
Gerresheimer AG2.25bn23.35m869.03m13.54k37.220.61993.110.38620.6760.67665.1540.590.54553.737.85185,328.900.63413.300.87164.6826.8930.041.165.840.52142.080.602241.292.287.90-5.526.3217.58-49.35
Eckert & Ziegler SE304.47m40.62m964.80m1.11k23.504.1116.893.170.64650.63284.853.700.65273.486.10280,619.308.858.6211.0610.4347.2548.5313.5514.182.3768.350.16632.1220.2210.6333.4012.7018.843.30
ChemoMetec A/S66.00m23.70m1.08bn172.0045.5212.3539.4216.3410.1710.1728.3337.500.65160.66625.542,679,973.0023.3927.4827.9334.0283.8380.5335.9036.413.0695.210.007948.7721.5018.2836.7825.8019.3536.08
Vitrolife AB322.53m-470.05m1.14bn1.15k--1.54--3.53-37.01-37.0125.3958.290.24073.445.242,987,837.00-35.09-9.46-36.79-9.8658.2457.81-145.74-49.192.7311.330.169---4.6822.53-1,077.00--68.156.58
El En SpA-100.00bn-100.00bn1.14bn1.42k--------------------------7.88--13.94--40.32--8.90------27.62-1.767.1416.0618.96-17.09--
Data as of Feb 06 2026. Currency figures normalised to GVS SpA's reporting currency: Euro EUR

Institutional shareholders

13.89%Per cent of shares held by top holders
HolderShares% Held
Van Lanschot Kempen Investment Management NVas of 08 May 20255.10m2.69%
Janus Henderson Investors UK Ltd.as of 31 Dec 20254.21m2.23%
Fidelity Management & Research Co. LLCas of 30 Nov 20252.65m1.40%
T. Rowe Price Hong Kong Ltd.as of 30 Sep 20252.55m1.35%
The Vanguard Group, Inc.as of 07 Jan 20262.49m1.31%
Mediolanum Gestione Fondi SGRpAas of 30 Sep 20251.96m1.04%
Degroof Petercam Asset Management SAas of 30 Sep 20251.94m1.03%
Amundi SGR SpAas of 28 Jun 20241.89m1.00%
Fideuram Asset Management SGR SpAas of 31 Dec 20251.80m0.95%
FIL Investments International (Italy)as of 30 Nov 20251.70m0.90%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.